Pure Global AI
NCT05650164Recruiting

Treatment Outcomes in Japanese RCC Patients Treated With Avelumab Plus Axitinib as First-line Therapy: Retrospective Study (J-DART2)

A Multicenter, NI, Retrospective, Observational Study Evaluating Real-World Treatment Outcomes in Japanese Patients With Metastatic Renal Cell Carcinoma (mRCC) Treated With Avelumab Plus Axitinib as First-line Therapy: J-DART2
PfizerClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Renal Cell Carcinoma
Drug/Device/Intervention
avelumab
Study type
Observational
Intervention type
drug
Sponsor & location
Primary sponsor
Pfizer
Location
Hirosaki,Kurume-shi,Kanazawa-shi,Osakasayama,Wakayama-shi,Yamagata-Shi,Kyoto, Japan
Timeline & enrollment
Phase
N/A
Start date
Jan 25, 2023
End date
Apr 30, 2023
Enrollment
150 participants
Primary outcome

Description of patient characteristics at baseline

Summary

This study is a multicenter, non-interventional, retrospective, medical chart review of
 patients with metastatic renal cell cancer(mRCC) treated with avelumab plus axitinib as a
 first-line therapy in Japan between 20 December 2019 and 17 October 2022. All decisions
 regarding clinical management and treatment of the participating patients were made by the
 investigator as part of standard care in real-world clinical setting and were not contingent
 upon the patient's participation in the study. Data will be collected if available per study
 site.

ICD-10 classifications
Malignant neoplasm of kidney, except renal pelvisMalignant neoplasm of renal pelvisSecondary malignant neoplasm of kidney and renal pelvisBenign neoplasm: KidneyBenign neoplasm: Renal pelvis
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05650164
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05650164 through Pure Global AI's free database. This phase not specified trial is sponsored by Pfizer and is currently Recruiting. The study focuses on Renal Cell Carcinoma. Target enrollment is 150 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.